Preliminary experience with a high bolus dose of tirofiban during percutaneous coronary intervention

Current Medical Research and Opinion

Volumn 19, Issue 1, 2003, Pages 28-33

  Danzi, Gian B ^a,b   Capuano, Cinzia ^a   Sesana, Marco ^a   Baglini, Roberto ^a  

^a Poliambulanza Hospital   (Italy)

^b Casa di Cura Poliambulanza   (Italy)

Author keywords

Angioplasty; Platelet inhibition; Stents; Tirofiban

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; TICLOPIDINE; TIROFIBAN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BIOASSAY; BLEEDING; BOLUS INJECTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; FEMALE; HEART INFARCTION; HEMATOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; STENT; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ITALY; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; TREATMENT OUTCOME; TYROSINE;

EID: 0037234675     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079902125001380     Document Type: Article

References (20)

1. TM). Cardiovasc Drug Rev 1999;17:199-224
2. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L. Comparison of two glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-94
3. Kabbani SS, Aggarwal A, Terrien EF, DiBattiste PM, Sobel BE, Schneider DJ. Suboptimal early inhibition of platelets by treatment with tirofiban and implication for coronary interventions. Am J Cardiol 2002;89:647-50
4. Herrmann HC, Swerkosz TA, Kapoor S, Tardiff DC, DiBattiste PM, Hirshfeld JW, Klugherz BD, Kolansky DM, Magness K, Valettas N, Wilensky RL. Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 2002;89:1293-7
5. Schneider DJ. Higher bolus doses of tirofiban augment inhibitory effects during the first hour after onset of treatment. Oral presentation at JIM Congressi - Rome, February 2002
6. Dangas G, Mehran R, Kokolis S, Feldman D, Satler LF, Pichard AD, Kent KM, Lansky AJ, Stone GW, Leon MB. Vascular complications after percutaneous coronary interventions following hemostasis with manual compression versus arteriotomy closure devices. J Am Coll Cardiol 2001;38:638-41
7. Tommasini G, Rubartelli P, Piaggio M. A deterministic approach to automated stenosis quantification. Cathet Cardiovasc Intervent 1999;48:435-45
8. Danzi GB, Pirelli S, Mauri L, Testa R, Ciliberto GR, Massa D, Lotto AA, Campolo L, Parodi O. Which variable of stenosis severity best describes the significance of an isolated left anterior descending coronary artery lesion? Correlation between quantitative coronary angiography, intracoronary Doppler measurements and high dose dipyridamole echocardiography. J Am Coll Cardiol 1998;31:526-33
9. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB III, Loop FD, Peterson KL, Reeves TJ, Williams DO, Winters WL. Guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures. Circulation 1988;78:486-502
10. Smith JW, Steinhubl SR, Lincoff M. Rapid platelet-function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation 1997;95:860-7
11. Wheeler GL, Braden GA, Steinhubl SR, Kereiakes DJ, Kottke-Marchant K, Michelson AD, Furman MI, Mueller MN, Moliterno DJ, Sane DC. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J 2002;143:602-11
12. Brown DL, Fann CS, Chang CJ. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention. Am J Cardiol 2001;87:537-54
13. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87
14. Steinhubl SR, Talley JD, Braden GA, Tcheng JE, Casterella PJ, Moliterno DJ, Navetta FI, Berger PB, Popma JJ, Dangas G, Gallo R, Sane DC, Saucedo JF, Jia G, Lincoff AM, Theroux P, Holmes DR, Teirstein PS, Kereiakes DJ. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention. Results of the GOLD (AU-Assessing Ultegra) Multicenter Study. Circulation 2001;103:2572-8
15. Osende JI, Fuster V, Lev EI, Shimbo D, Rauch U, Marmur JD, Richard M, Varon D, Badimon JJ. Testing platelet activation with a shear-dependent platelet function test vs. aggregation based tests. Circulation 2001;103:1488-91
16. Michalis LK, Tambaki AP, Katsoruras CS, Goudevenos JA, Kolettis T, Adamides K, Tselepis AD, Sideris DA. Platelet hyperaggregability to platelet activating factor (PAF) in non-ST elevation acute coronary syndromes. Curr Med Res Opin 2002;18:108-12
17. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356:2037-44
18. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92
19. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96
20. Lindsay J Jr, Pinnow EE, Pichard AD. Frequency of major adverse cardiac events within one month of coronary angioplasty: a useful measure of operator performance. J Am Coll Cardiol 1999 34:1916-23